Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(86%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
2
29%
Ph not_applicable
1
14%
Ph phase_3
1
14%
Ph phase_2
3
43%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

7

all time

Status Distribution
Active(6)
Completed(1)

Detailed Status

Recruiting5
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 23 (42.9%)
Phase 31 (14.3%)
N/A1 (14.3%)

Trials by Status

active_not_recruiting114%
recruiting571%
completed114%

Recent Activity

6 active trials
Showing 5 of 7
recruitingnot_applicable

A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia

NCT07499284
recruitingphase_1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

NCT07020533
completedphase_2

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

NCT03159702
recruitingphase_1

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

NCT05757310
active_not_recruitingphase_3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07499284Not Applicable

A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia

Recruiting
NCT07020533Phase 1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Recruiting
NCT03159702Phase 2

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

Completed
NCT05757310Phase 1

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Recruiting
NCT05457556Phase 3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Active Not Recruiting
NCT04356469Phase 2

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

Recruiting
NCT04414046Phase 2

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7